2017-09 Antibacterial agents in clinical development – An analysis of the antibacterial clinical development pipeline, including tuberculosis. OMS 45 pags

September 22, 2017 at 8:03 am

Contents:

Acknowledgements

Abbreviations and acronyms

Executive summary

  1. Introduction
  2. Methods and search results

2.1 Scope and inclusion criteria

2.2 Assessment of activity against priority pathogens and innovativeness

  1. Agents in clinical development

3.1 Antibiotics potentially active against pathogens on the WHO priority  pathogens list

3.2 Combinations without new chemical entities

3.3 Agents in development for treating tuberculosis

3.4 Agents in development for treating Clostridium difficile infections

3.5 Biological agents

3.6 Agents that are not under active development or for which there is no  recent information

  1. Analysis of the clinical pipeline
  2. Outlook and discussion

5.1 The current clinical pipeline is insufficient against pathogens on the  WHO priority pathogens list and TB.

5.2 More innovative approaches are required, but there are scientific  challenges.

5.3 Outlook: More work is required to fill the pipeline.

5.4 Methodological considerations

  1. References

Annex 1. Search strategy and results

Annex 2. Declarations of interests of advisory group members

PDF

http://apps.who.int/iris/bitstream/10665/258965/1/WHO-EMP-IAU-2017.11-eng.pdf

 

Advertisements

Entry filed under: Antimicrobianos, Micobacterias, REPORTS, Resistencia bacteriana, Update.

Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth Infective endocarditis in patients with cancer: a consequence of invasive procedures or a harbinger of neoplasm? –  A prospective, multicenter cohort


Calendar

September 2017
M T W T F S S
« Aug   Oct »
 123
45678910
11121314151617
18192021222324
252627282930  

Most Recent Posts


%d bloggers like this: